Endocrinology and Metabolism Fellowship Program - The University of Connecticut School of Medicine

Andrew Arnold, M.D.

Faculty Title:
Professor of Medicine; Murray-Heilig Chair in Molecular Medicine and
Chief, Division of Endocrinology and Metabolism

Office Locations:
The Carole and Ray Neag
Comprehensive Cancer Center
UConn Health Center
263 Farmington Avenue
Farmington, CT 06030

Specialties:
Parathyroid Gland Tumors and Other Parathyroid Disorders
Multiple Endocrine Neoplasia Disorders

Board Certification:
American Board of Internal Medicine
American Board of Internal Medicine: Endocrinology and Metabolism

Brief Biosketch:
M.D., Harvard Medical School; residency in internal medicine, University of Chicago; fellowship at NIH in molecular oncology; clinical fellowship in endocrinology at Massachusetts General Hospital. Previous faculty appointment: Harvard Medical School/MGH. Dr Arnold is a leader in the field of endocrine neoplasia and the molecular basis of parathyroid disorders; his research accomplishments include discovery of the cyclin D1 oncogene and identifying HRPT2 mutation as the central molecular cause of parathyroid cancer. Dr. Arnold's honors include the Fuller Albright Award and the Louis Avioli Founders Award from the American Society for Bone and Mineral Research; the Gerald D. Aurbach Award from The Endocrine Society; and election to the American Society for Clinical Investigation and the Association of American Physicians.

Selected Publications:

Imanishi Y, Hosokawa Y, Yoshimoto K, Schipani E, Mallya S, Papanikolaou A, Kifor O, Tokura T, Sablosky M, Ledgard F, Gronowicz G, Wang TC, Schmidt EV, Hall C, Brown EM, Bronson R, Arnold A. Primary hyperparathyroidism caused by parathyroid-targeted overexpression of cyclin D1 in transgenic mice. J Clin Invest 2001; 107:1093-1102

Shattuck TM, Välimäki S, Obara T, Gaz RD, Clark OH, Shoback D, Wierman ME, Tojo K, Robbins CM, Carpten JD, Farnebo L-O, Larsson C, Arnold A. Somatic and germline mutations of the HRPT2 gene in sporadic parathyroid carcinoma. N Engl J Med 2003; 349:1722-9.

Shattuck TM, Westra WH, Ladenson PW, Arnold A. Independent clonal origins of distinct tumor foci in multifocal papillary thyroid carcinoma. N Engl J Med 2005; 352:2406-12.

Mallya SM, Gallagher JJ, Wild YK, Kifor O, Costa-Guda J, Saucier K, Brown EM, Arnold A. Abnormal parathyroid cell proliferation precedes biochemical abnormalities in a mouse model of primary hyperparathyroidism. Mol Endocrinol 2005; 19:2603-9.

Krebs LJ, Shattuck TM, Arnold A. HRPT2 mutational analysis of typical sporadic parathyroid adenomas. J Clin Endocrinol Metab 2005; 90:5015-7.

Kelly TG, Shattuck TM, Reyes-Mugica M, Stewart AF, Simonds WF, Udelsman R, Arnold A, Carpenter TO. Surveillance for early detection of aggressive parathyroid disease: carcinoma and atypical adenoma in familial isolated hyperparathyroidism associated with a germline HRPT2 mutation. J Bone Miner Res 2006; 21:1666-71.
Costa-Guda J, Arnold A. Absence of stabilizing mutations of b-catenin encoded by CTNNB1 exon 3 in a large series of sporadic parathyroid adenomas. J Clin Endocrinol Metab 2007; 92:1564-6.

Juhlin CC, Villablanca A, Sandelin K, Haglund F, Nordenström J, Forsberg L, Bränström R, Obara T, Arnold A, Larsson C, Höög A. Parafibromin immunoreactivity: its use as an additional diagnostic marker for parathyroid tumor classification. Endocr Relat Cancer 2007; 14:501-12.

Costa-Guda J, Tokura T, Roth SI, Arnold A. Mitochondrial DNA mutations in oxyphilic and chief cell parathyroid adenomas. BMC Endocr Disord 2007, in press.